(Q45861920)

17 December 2017

title

Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. (English)

1 reference

17 December 2017

author name string

Kayaga J

1

1 reference

17 December 2017

Souberbielle BE

2

1 reference

17 December 2017

Sheikh N

3

1 reference

17 December 2017

Morrow WJ

4

1 reference

17 December 2017

Scott-Taylor T

5

1 reference

17 December 2017

Vile R

6

1 reference

17 December 2017

Chong H

7

1 reference

17 December 2017

Dalgleish AG

8

1 reference

17 December 2017

publication date

1 August 1999

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

6

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

page(s)

1475-1481

1 reference

17 December 2017

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Identification of proliferating dendritic cell precursors in mouse blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Antigen presentation to cytotoxic T lymphocytes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Speculations on the Role of Ultraviolet Radiation in the Development of Malignant Melanoma4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

7 January 2021

Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

7 January 2021

Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

7 January 2021

A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

7 January 2021

Expression of mage genes by non-small-cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

7 January 2021

Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300961

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3300961

1 reference

17 December 2017

Dimensions Publication ID

1053568568

0 references

1 reference

17 December 2017